223 related articles for article (PubMed ID: 28423716)
1. Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.
Garczyk S; Klotz N; Szczepanski S; Denecke B; Antonopoulos W; von Stillfried S; Knüchel R; Rose M; Dahl E
Oncotarget; 2017 May; 8(22):36246-36265. PubMed ID: 28423716
[TBL] [Abstract][Full Text] [Related]
2. NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling.
Lin TY; Wu FJ; Chang CL; Li Z; Luo CW
Oncotarget; 2016 Mar; 7(9):10228-42. PubMed ID: 26849234
[TBL] [Abstract][Full Text] [Related]
3. Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.
Przygodzka P; Sochacka E; Soboska K; Pacholczyk M; Papiewska-Pająk I; Przygodzki T; Płociński P; Ballet S; De Prins A; Boncela J
J Exp Clin Cancer Res; 2021 Sep; 40(1):283. PubMed ID: 34493299
[TBL] [Abstract][Full Text] [Related]
4. Identifying a Neuromedin U Receptor 2 Splice Variant and Determining Its Roles in the Regulation of Signaling and Tumorigenesis In Vitro.
Lin TY; Huang WL; Lee WY; Luo CW
PLoS One; 2015; 10(8):e0136836. PubMed ID: 26317338
[TBL] [Abstract][Full Text] [Related]
5. Ovarian regulation of neuromedin U and its local actions in the ovary, mediated through neuromedin U receptor 2.
Lin TY; Wu FJ; Lee WY; Hsiao CL; Luo CW
Am J Physiol Endocrinol Metab; 2013 Apr; 304(8):E800-9. PubMed ID: 23423171
[TBL] [Abstract][Full Text] [Related]
6. Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U.
Kasper JM; McCue DL; Milton AJ; Szwed A; Sampson CM; Huang M; Carlton S; Meltzer HY; Cunningham KA; Hommel JD
Biol Psychiatry; 2016 Dec; 80(11):878-887. PubMed ID: 27105831
[TBL] [Abstract][Full Text] [Related]
7. Characterization of neuromedin U (NMU), neuromedin S (NMS) and their receptors (NMUR1, NMUR2) in chickens.
Wan Y; Zhang J; Fang C; Chen J; Li J; Li J; Wu C; Wang Y
Peptides; 2018 Mar; 101():69-81. PubMed ID: 29288685
[TBL] [Abstract][Full Text] [Related]
8. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
[TBL] [Abstract][Full Text] [Related]
9. Cloning and expression patterns of neuromedin U and its receptors in pigs.
Li X; Niu M; Su J; Ma Z; Jin M; Qiao W; Zhang Y; Feng Y; An N; Hou Y; Yang S; Chuan S; Lei Z
Neuropeptides; 2017 Aug; 64():47-60. PubMed ID: 28434792
[TBL] [Abstract][Full Text] [Related]
10. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
[TBL] [Abstract][Full Text] [Related]
11. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
[TBL] [Abstract][Full Text] [Related]
12. Neuromedin U (NMU) regulates osteoblast differentiation and activity.
Hsiao YT; Jestes KJ; Jackson KL; Zukosky T; Squire ME; Hum JM; Lowery JW
Biochem Biophys Res Commun; 2020 Apr; 524(4):890-894. PubMed ID: 32057362
[TBL] [Abstract][Full Text] [Related]
13. Neuromedin U receptor 2 knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat food and leads to increased body weight.
Benzon CR; Johnson SB; McCue DL; Li D; Green TA; Hommel JD
Neuroscience; 2014 Jan; 258():270-9. PubMed ID: 24269937
[TBL] [Abstract][Full Text] [Related]
14. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice.
Egecioglu E; Ploj K; Xu X; Bjursell M; Salomé N; Andersson N; Ohlsson C; Taube M; Hansson C; Bohlooly-Y M; Morgan DG; Dickson SL
Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E708-16. PubMed ID: 19584200
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of neuromedin U mRNA expression in the rat pars tuberalis by melatonin.
Aizawa S; Sakata I; Nagasaka M; Higaki Y; Sakai T
PLoS One; 2013; 8(7):e67118. PubMed ID: 23843987
[TBL] [Abstract][Full Text] [Related]
16. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
[TBL] [Abstract][Full Text] [Related]
17. Activation of neuromedin U type 1 receptor inhibits L-type Ca2+ channel currents via phosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway in mouse hippocampal neurons.
Zhang Y; Jiang D; Zhang J; Wang F; Jiang X; Tao J
Cell Signal; 2010 Nov; 22(11):1660-8. PubMed ID: 20599609
[TBL] [Abstract][Full Text] [Related]
18. Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
Martinez VG; Crown J; Porter RK; O'Driscoll L
Int J Cancer; 2017 Jun; 140(12):2771-2784. PubMed ID: 28340506
[TBL] [Abstract][Full Text] [Related]
19. Neuromedin U directly stimulates growth of cultured rat calvarial osteoblast-like cells acting via the NMU receptor 2 isoform.
Rucinski M; Ziolkowska A; Tyczewska M; Szyszka M; Malendowicz LK
Int J Mol Med; 2008 Sep; 22(3):363-8. PubMed ID: 18698496
[TBL] [Abstract][Full Text] [Related]
20. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
